Filtered By:
Condition: Atrial Fibrillation
Management: National Institute for Health and Clinical Excelle
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 31 results found since Jan 2013.
NICE guidance supports new blood pressure device that can detect atrial fibrillation
The guidance backs use of WatchBP Home A, which could reduce the incidence of atrial fibrillation-related stroke by improving early detection.
The guidance also recommends that WatchBP Home A should be considered for use in people with suspected hypertension (high blood pressure) or those being screened for hypertension in primary care.
Source: NHS Networks - January 21, 2013 Category: UK Health Authors: Maria Axford Source Type: news
NICE Final Appraisal Determination on ELIQUIS®
Bristol-Myers Squibb and Pfizer Ltd. have announced that the National Institute for Health and Clinical Excellence (NICE) has issued a fast-tracked Final Appraisal Determination (FAD) recommending the oral anticoagulant Eliquis (apixaban) as an option for preventing stroke and systemic embolism, in patients with non-valvular atrial fibrillation (AF) with one or more risk factors.
Source: Pharmacy Europe - January 24, 2013 Category: Drugs & Pharmacology Source Type: news
New stroke prevention treatment recommended by NICE
Atrial
fibrillation (AF) is the most common
cause of irregular heart beat. It can cause the heart rhythm to become
disorganised, and on occasion too fast, leading to the inefficient pumping of
blood around the body.
Source: NHS Networks - February 28, 2013 Category: UK Health Authors: Karen Topping Source Type: news
Supporting the commissioning of anticoagulation therapy for adults
This resource supports commissioners to review how anticoagulation therapy is currently initiated, provided, monitored and reviewed in their local area with particular consideration to the introduction of the novel oral anticoagulants. NICE recommendations for rivaroxaban, dabigatran and apixaban for stroke prevention in people with atrial fibrillation and rivaroxaban for treatment of deep vein thrombosis provide people who have these conditions with more choices of medication. This will have an impact on the commissioning of anticoagulation services at a local level, with an anticipated reduction in vitamin K antagonist monitoring services.
Source: NHS Networks - May 23, 2013 Category: UK Health Authors: Maria Axford Source Type: news
GPs to review aspirin use in atrial fibrillation patients
NICE calls for increased uptake of anticoagulantsRelated items from OnMedicaAlteplase use linked to reduction in disability after strokeGPs should screen over 65s for atrial fibrillationAtrial fibrillation raises risk of cognitive problems Statin use after stroke not linked to bleedsNew guidance to prevent strokes
Source: OnMedica Latest News - June 19, 2014 Category: UK Health Source Type: news
Editorial Time for action on atrial fibrillation
The incidence of atrial fibrillation, a common and treatable risk factor for ischaemic stroke, is predicted to increase in the coming decades, elevating the status of this arrhythmia to that of a public health priority. The growing importance of this condition is reflected by the publication in July, 2015, of two documents: the research report for the Future of Anticoagulation Initiative on the future of atrial fibrillation management in Europe; and the UK National Institute for Health and Care Excellence (NICE) Quality Standard on the treatment and management of atrial fibrillation.
Source: Lancet Neurology - August 10, 2015 Category: Neurology Authors: The Lancet Neurology Tags: Editorial Source Type: research
NICE approves new oral anti-coagulant for atrial fibrillation
The drug edoxaban has been given the official seal of approval for NHS use in preventing stroke and blood clots in patients with a common heart disorder.
Source: Nursing Times Breaking News - September 24, 2015 Category: Nursing Source Type: news
A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference
This report ends with a list of priorities for research in AF patients.
Source: Europace - February 3, 2016 Category: Cardiology Authors: Kirchhof, P., Breithardt, G., Bax, J., Benninger, G., Blomstrom-Lundqvist, C., Boriani, G., Brandes, A., Brown, H., Brueckmann, M., Calkins, H., Calvert, M., Christoffels, V., Crijns, H., Dobrev, D., Ellinor, P., Fabritz, L., Fetsch, T., Freedman, S. B., Tags: EHRA CONSENSUS STATEMENT Source Type: research
RPS responds to NICE Guideline on Atrial Fibrillation
Responding to new guidance from NICE on how best to treat people at serious risk of a stroke because of an abnormal heart rhythm, known as atrial fibrillation (AF), Helen Williams, Consultant Pharmacist and RPS spokesperson on ca
Source: Royal Pharmaceutical Society News - June 17, 2014 Category: Drugs & Pharmacology Source Type: news
NICE aims to prevent 8,000 strokes
NICE is calling for GPs and CCGs to focus on preventing 8,000 strokes a year.
New NICE indicators will help GPs and CCGs improve the identification and management of atrial fibrillation (AF) – a common heart condition that causes an irregular heartbeat and increases the risk of stroke.
Source: NHS Networks - August 2, 2016 Category: UK Health Source Type: news
124 GP-led anticoagulation counselling for non-valvular atrial fibrillation (AF) in the community is neither comprehensive nor accurate: Results from a service improvement project.
Background: Stroke risk in NVAF can be reduced significantly by anticoagulation with either warfarin or the non- vitamin K antagonist (NOACs). NICE recommendations state that NOACs are as efficacious but also associated with significantly less intracranial bleeding compared to Warfarin and in this sense are safer than warfarin. Additionally NOACs do not require regular monitoring of their anticoagulant effects and therefore offer convenience to the patient. However they are not as tried and tested as warfarin and at the time of our study, did not have an available agent to reverse their effects in the event of a bleeding c...
Source: Europace - October 5, 2017 Category: Cardiology Source Type: research
‘We’re Not As Healthy As We Should Be.’ Fitbit CEO James Park Discusses New AFib Detection Partnership With Bristol-Myers Squibb-Pfizer
“We’re not as healthy as we should be.”
That’s what Fitbit CEO and co-founder James Park said at Thursday’s TIME 100 Health Summit, where MSNBC anchor Stephanie Ruhle interviewed him about the company’s future in the health care space, the impact of wearables and just how active Fitbit’s 30 million active users really are.
Ruhle talked with Park about Fitbit’s position as one of the first major wearables company to have gone public, one that led the charge in terms of mass market adoption but has lost ground to competitors offering more advanced wearable devices, as well as ...
Source: TIME: Health - October 17, 2019 Category: Consumer Health News Authors: Patrick Lucas Austin Tags: Uncategorized fitness HealthSummit19 technology Source Type: news
NICE recommends implantable monitor to identify atrial fibrillation after stroke
Source: BMJ News - January 14, 2020 Category: General Medicine Source Type: research
IJERPH, Vol. 19, Pages 4467: A Nurse-Led Integrated Chronic Care E-Enhanced Atrial Fibrillation (NICE-AF) Clinic in the Community: A Preliminary Evaluation
This study aims to provide a preliminary evaluation of the effectiveness of a Nurse-led Integrated Chronic care E-enhanced Atrial Fibrillation (NICE-AF) clinic in the community. The NICE-AF clinic was led by an advanced practice nurse (APN) who collaborated with a family physician. The clinic embodied integrated care and shifted from hospital-based, physician-centric care. Regular patient education, supplemented by a specially curated webpage, fast-tracked appointments for hospital-based specialised investigations, and teleconsultation with a hospital-based cardiologist were the highlights of the clinic. Forty-three partic...
Source: International Journal of Environmental Research and Public Health - April 7, 2022 Category: Environmental Health Authors: Brigitte Fong Yeong Woo Wilson Wai San Tam Taiju Rangpa Wei Fong Liau Jennifer Nathania Toon Wei Lim Tags: Article Source Type: research
Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations
Eur J Intern Med. 2022 May 4:S0953-6205(22)00166-2. doi: 10.1016/j.ejim.2022.04.023. Online ahead of print.ABSTRACTClinical practice in atrial fibrillation (AF) patient management is constantly evolving. In the past 3 years, various new AF guidelines or focused updates have been published, given this rapidly evolving field. In 2019, the American College of Cardiology/American Heart Association published a focused update of the 2014 guidelines. In 2020, both the European Society of Cardiology and the Canadian Cardiovascular Society released their new guidelines. Finally, the most recent guidelines were those published in 20...
Source: European Journal of Internal Medicine - May 7, 2022 Category: Internal Medicine Authors: Jacopo Francesco Imberti Davide Antonio Mei Marco Vitolo Niccol ò Bonini Marco Proietti Tatjana Potpara Gregory Y H Lip Giuseppe Boriani Source Type: research
